A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma
Liver Cancer · 30.03.2026 · 1-9
DOI: 10.1159/000551630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 30.03.2026. Verfasst von Anthony B El-Khoueiry und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Botensilimab (BOT) is a fragment crystallizable (Fc)-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody with differentiated mechanisms of action, designed to extend therapy to cold/poorly immunogenic solid tumors. Patients with hepatocellular carcinoma (HCC) who progress on or after first-line immunotherapy have limited treatment options. Here, we report findings from a phase 1b study of BOT plus balstilimab (BAL; anti-programmed cell death protein 1 [PD-1] antibody) in previously treated patients with HCC.
Methods
This is an open-label, nonrandomized, phase 1b, multicenter study of BOT±BAL in patients with advanced solid tumors. The study began with dose escalation (3 + 3 design) then dose expansion with multiple disease-specific cohorts. An expanded cohort of 19 patients with HCC who progressed on or after prior immunotherapy (primarily atezolizumab/bevacizumab) are included in this analysis. Patients with HCC received BOT intravenously at 1 or 2 mg/kg once every 6 weeks for up to 2 years plus BAL intravenously 3 mg/kg once every 2 weeks, for up to 2 years. Endpoints included safety, objective response rate (ORR), disease control rate, duration of response, and progression-free survival (PFS). Overall survival (OS) was an exploratory endpoint.
Results
Among 18 efficacy evaluable patients (with ≥1 post-baseline 6-week imaging scan), ORR was 17% (3/18; 95% CI: 4–41), and 18-week clinical benefit rate (a complete or partial response or stable disease) 50% (9/18; 95% CI: 26–74). Median PFS was 4.4 months (95% CI: 1.4–6.9), and median OS was 12.3 months (95% CI: 8.4–21.4). Thirteen patients (68%) experienced any-grade immune-mediated treatment-related adverse events (TRAEs), with 37% (7/19) grade 3. The most common immune-mediated TRAEs included diarrhea/colitis (37% [7/19]; 16% grade 3 [3/19]), hepatitis (21% [4/19]; 16% grade 3 [3/19]), and dermatologic events (21% [4/19]; 5% grade 3 [1/19]). There were no treatment-related deaths or new safety signals outside of the class.
Conclusions
The BOT+BAL combination demonstrated durable responses and manageable safety in treatment-refractory patients with HCC previously treated with immunotherapy, supporting further investigation in randomized studies. Despite the small sample size and high percentage of patients with albumin-bilirubin grade 2 liver disease, these results provide early evidence of antitumor activity in a difficult-to-treat disease setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
- University of Colorado Cancer Center, Aurora, CO, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Weill Medical College at Cornell University, New York, NY, USA.
- Trinity College Dublin, Dublin, Ireland.
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
El-Khoueiry, A. B., Lieu, C. H., Abou-Alfa, G. K., Tsimberidou, A. M., Mahadevan, D., Hanna, D. L., Bockorny, B., Wilky, B. A., Leal, A., Stebbing, J., Avagyan, M., Wu, W., Chand, D., Grossman, J. E., Johnson, B., & Bullock, A. J. (2026). A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma. Liver Cancer, 1-9. https://doi.org/10.1159/000551630
Vancouver
El-Khoueiry AB, Lieu CH, Abou-Alfa GK, Tsimberidou AM, Mahadevan D, Hanna DL, et al. A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma. Liver Cancer. 2026:1-9. doi:10.1159/000551630
BibTeX
@article{ElKhoueiry2026,
author = {El-Khoueiry, Anthony B and Lieu, Christopher H and Abou-Alfa, Ghassan K and Tsimberidou, Apostolia M and Mahadevan, Daruka and Hanna, Diana L and Bockorny, Bruno and Wilky, Breelyn A and Leal, Alexis and Stebbing, Justin and Avagyan, Manushak and Wu, Wei and Chand, Dhan and Grossman, Joseph E and Johnson, Benny and Bullock, Andrea J},
title = {A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma},
journal = {Liver Cancer},
year = {2026},
pages = {1--9},
doi = {10.1159/000551630}
}
EUVIMED